Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Chronic Rhinosinusitis With Nasal Polyposis
CHENGDU, China, Dec. 23, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (the "sNDA") of Stapokibart (anti-IL-4Rα monoclonal antibody, trade name: 康悦达, R&D codename: CM310), for the treatment of chronic rhinosinusitis with nasal polyposis. The approval is based on a...
Porton Pharma Solutions and Dragon Sail Pharmaceutical Form Strategic Partnership to Build a New Ecosystem for ADC Drug Development, Production, and Supply Chain
CHONGQING, China, Dec. 23, 2024 /PRNewswire/ -- On December 20, 2024, Porton Pharma Solutions (hereinafter referred to as "company" or "Porton") and Dragon Sail Pharmaceutical (Shanghai) Co., Ltd. (a subsidiary of Guilin Sanjin, hereinafter referred to as "Dragon Sail Pharmaceutical") formally signed a strategic cooperation agreement in Guilin, southern of China. This collaboration aims to carry out in-depth cooperation in...
From Campus to CES®: KHU Startups and Students on a Global Mission
Four Startups, Student Supporters, and Research Programs from Kyung Hee to Highlight Innovative Startup Achievements and Facilitate Global Market Expansion SEOUL, South Korea, Dec. 23, 2024 /PRNewswire/ -- Kyung Hee University (President Jinsang Kim) is preparing to leave its mark on CES® 2025, the world's premier electronics and IT exhibition. Supported by the LINC 3.0 initiative and the University-Industrial...
THE STATE OF GLOBAL OPTIMISM REVEALED BY LG IN NEW SURVEY
Company Unveils the Biggest Topics of Global Optimism: Entertainment, AI and Healthcare. SEOUL, South Korea, Dec. 23, 2024 /PRNewswire/ -- According to the latest research by LG Electronics (LG), 48 percent of consumers say they are more optimistic now than they were compared to six months ago. LG reveals state...
Inspur Smart Healthcare Participates in GITEX IMPACT 2024 Exhibition
DUBAI, UAE, Dec. 23, 2024 /PRNewswire/ -- From October 13th to 16th, the GITEX IMPACT 2024, Dubai's Carbon Neutrality and Technology Exhibition, was held in Dubai. Organized by the Ministry of Economy and Ministry of Tourism of the United Arab Emirates, the exhibition focused on the forefront of sustainable development technologies, encompassing a wide range of sectors including...
Kickstart 2025 with Expert Holiday Health Tips
KUALA LUMPUR, Malaysia, Dec. 23, 2024 /PRNewswire/ -- As Pantai Hospital Kuala Lumpur (PHKL) celebrates 50 years of excellence in patient care, it's a moment to reflect on how small, proactive steps can make a significant difference to your health. The holiday season is a time of joy, but it also brings unique challenges, from indulgent meals to increased stress...
Aptamer developed by HKBU for treating rare bone disease ‘X-linked hypophosphatemia’ receives Orphan Drug Designation and Rare Pediatric Disease Designation by U.S. FDA
HONG KONG, Dec. 23, 2024 /PRNewswire/ -- A research led by Hong Kong Baptist University (HKBU) and the Shanghai Sixth People's Hospital Affiliated to School of Medicine at Shanghai Jiao Tong University (Shanghai Sixth People's Hospital) has discovered that an aptamer developed by HKBU can be used to treat X-linked hypophosphatemia (XLH), a rare bone disease. The aptamer, originally...
SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore
SCG Cell Therapy signed a Memorandum of Understanding (MoU) with A*STAR Bioprocessing Technology Institute (A*STAR BTI) and Nucleic Acid Therapeutics Initiative (NATi) to advance ribonucleic acid (RNA)-based therapeutic manufacturing process development and clinical translation. The parties will work together to fast-track RNA based therapeutics commercialisation from concept to patient treatment. Collaborative projects include RNA-based cell and gene therapy...
CStone Announces Submission of Clinical Trial Application in Australia for CS2009, an Innovative PD-1/VEGF/CTLA-4 Trispecific Antibody
SHANGHAI, Dec. 23, 2024 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, announced today the submission of clinical trial application in Australia for CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody), a leading asset from the Company's Pipeline 2.0 to address various solid tumors. This first-in-human study has also been registered...
Macrogen Consortium win tender for National Bio Big Data Project
Illumina is proud to be selected as sequencing technology partner to the Macrogen Consortium. SEOUL, South Korea, Dec. 23, 2024 /PRNewswire/ -- Macrogen a global healthcare company that specializes in precision medicine and Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today that they are honoured...
